ArticleFrontiers in cellular and infection microbiology2026
Molecular confirmation of transfusion-transmitted dengue virus infection following platelet transfusion in the Chinese mainland.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dengue virus (DENV) is considered an emerging threat to blood safety. While transfusion-transmitted DENV (TT-DENV) cases have been documented, TT-DENV has never been reported in Chinese mainland. In this study, a retrospective investigation was conducted after two patients developed dengue fever (DF) following apheresis platelet (PLT) transfusion from the same healthy donor. Methods: Blood samples from the recipients and the donor were tested for DENV RNA by nucleic acid testing (NAT). Nonstructural protein 1 (NS1) antigen and anti-DENV immunoglobulin M/G (IgM/IgG) antibodies were detected by ELISA. To confirm transmission, DENV E gene fragments were amplified, and whole-genome sequences were obtained by metagenomic next-generation sequencing (mNGS). Results: Our results revealed that the PLT donor was asymptomatic, tested positive for DENV RNA, and negative for anti-DENV IgM/IgG antibodies at donation. After donation, no dengue-like symptoms was developed. Seroconversion was observed at day 21 postdonation. After receiving the DENV-positive PLT unit, recipient 1 had DF only, while recipient 2 developed DF together with headache, joint/muscle pain, and rash. After transfusion, both recipients were positive for DENV RNA and NS1 while negative for anti-DENV IgM/IgG antibodies. Viral sequences from the donor and recipients were identical and belonged to DENV-2. Conclusions: To our knowledge, this is the first TT-DENV case reported in the Chinese mainland, revealing the necessity of revising current donor deferral policies and testing strategies that predominantly rely on symptoms and travel history.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.